T Cell Therapy for EBV-Positive Nasopharyngeal Carcinoma

One of the causes of Nasopharyngeal Carcinoma (NPC) is an oncogenic protein made by the Epstein-Barr virus (EBV), referred to as the latent membrane protein 1 (LMP1). EBV-specific cytotoxic T cells (EBV-CTLs) therapy is a process where T-cells are removed from a patient’s tumor and induced to target the oncogenic EBV proteins. In this trial, 56% of patients with advanced NPC achieved tumor regression or disease stabilization. I like this approach because not only does offer increase survival, but it is non-toxic and has minimal side effects, unlike the standard treatment.

T-Cell Therapy for Nasopharyngeal Carcinoma.

The following link is a database of clinical trials using this and other treatment approaches for NPC.

LINK TO NPC CLINICAL TRIALS


Speak Your Mind

*